PCMC
CCCC icon

Planning Capital Management Corporation’s C4 Therapeutics CCCC Stock Holding History

Planning Capital Management Corporation’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$200 Hold
35
– – ﹤0.01% 701
2024
Q2 		$162 Buy
+35
New +$209 ﹤0.01% 651

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Planning Capital Management Corporation's CCCC Position: Q3 2024 in Review

Planning Capital Management Corporation held its C4 Therapeutics (CCCC) position steady in Q3 2024 at 35 shares worth $200. The position accounts for ﹤0.01% of the portfolio, ranked #701.

Planning Capital Management Corporation first reported a position in CCCC in Q2 2024 and has held it in 2 quarters since. 118 funds tracked by Wall St. Rank hold CCCC as of Q3 2024.

  • Planning Capital Management Corporation held 35 shares of C4 Therapeutics worth $200 as of Q3 2024.
  • Planning Capital Management Corporation left its C4 Therapeutics share count unchanged in Q3 2024.
  • C4 Therapeutics made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #701 holding.
  • Planning Capital Management Corporation first reported a position in C4 Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 118 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.